Since MKK4 requires sphingosine binding for autophosphorylation, a reduction in activity can be achieved by using PQA-11 as a lead structure for the further development of neuroprotective drugs and the treatment of neurodegenerative diseases such as Alzheimer’s or Parkinson’s disease. Here, MAP2K4 is linked to neurodegenerative disease.